Evidence map›Paper›PMID 31878963›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.

Cinzia Zucchini, Maria Cristina Manara, Camilla Cristalli, Marianna Carrabotta, Sara Greco, Rosa Simona Pinca, Cristina Ferrari, Lorena Landuzzi, Michela Pasello, Pier-Luigi Lollini and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Biomechanical Aspects in Bone Tumor Engineering.Tissue engineering. Part B, Reviews · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. The Induced Expression ofInternational journal of molecular sciences · 2022
    Article
  17. Acquired temozolomide resistance in MGMTCell death & disease · 2022
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Cinzia ZucchiniDepartment of Experimental, Diagnostic and Specialty Medicine, (DIMES), University of Bologna, Via Massarenti 9, 40126, Bologna, BO, Italy. cinzia.zucchini@unibo.it.
Maria Cristina ManaraExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10, 40136, Bologna, Italy.
Camilla CristalliExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10, 40136, Bologna, Italy.
Marianna CarrabottaExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10, 40136, Bologna, Italy.
Sara GrecoExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10, 40136, Bologna, Italy.
Rosa Simona PincaExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10, 40136, Bologna, Italy.
Cristina FerrariExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10, 40136, Bologna, Italy.
Lorena LanduzziExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10, 40136, Bologna, Italy.
Michela PaselloExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10, 40136, Bologna, Italy.
Pier-Luigi LolliniDepartment of Experimental, Diagnostic and Specialty Medicine, (DIMES), University of Bologna, Via Massarenti 9, 40126, Bologna, BO, Italy.
Marco GambarottiDepartment of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Davide Maria DonatiClinica Ortopedica III, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Katia ScotlandiExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10, 40136, Bologna, Italy. katia.scotlandi@ior.it.
Istituto Ortopedico Rizzoli · ITUniversity of Bologna · IT

Funding

Alleanza contro il Cancro ACC-Genomics WG SarcomaAssociazione Italiana per la Ricerca sul Cancro IG 2013-14049Associazione Onlus 'il Pensatore: Matteo Amitrano' and 'Liberi di Vivere Luca Righi NAERANET TRANSCAN-2_TORPEDO ER-2015-2360405Horizon2020-IMI2-ITCC-P4 116064
6 · The paper itself

Abstract

backgroundThe treatment of metastatic osteosarcoma (OS) remains a challenge for oncologists, and novel therapeutic strategies are urgently needed. An understanding of the pathways that regulate OS dissemination is required for the design of novel treatment approaches. We recently identified Rho-associated coiled-coil containing protein kinase 2 (ROCK2) as a crucial driver of OS cell migration. In this study, we explored the impact of ROCK2 disruption on the metastatic capabilities of OS cells and analyzed its functional relationship with Yes-associated protein-1 (YAP), the main transcriptional mediator of mechanotransduction signaling.

methodsThe effects of ROCK2 depletion on metastasis were studied in NOD Scid gamma (NSG) mice injected with U-2OS cells in which ROCK2 expression had been stably silenced. Functional studies were performed in vitro in human U-2OS cells and in three novel cell lines derived from patient-derived xenografts (PDXs) by using standard methods to evaluate malignancy parameters and signaling transduction. The nuclear immunostaining of YAP and the evaluation of its downstream targets Cysteine Rich Angiogenic Inducer 6, Connective Tissue Growth Factor and Cyclin D1 by quantitative PCR were performed to analyze YAP activity. The effect of the expression and activity of ROCK2 and YAP on tumor progression was analyzed in 175 OS primary tumors.

resultsThe silencing of ROCK2 markedly reduced tumor growth and completely abolished the metastatic ability of U-2OS cells. The depletion of ROCK2, either by pharmacological inhibition or silencing, induced a dose- and time-dependent reduction in the nuclear expression and transcriptional activity of YAP. The nuclear expression of YAP was observed in 80/175 (46%) tumor samples and was significantly correlated with worse patient prognosis and a higher likelihood of metastasis and death. The use of verteporfin, a molecule that specifically inhibits the TEAD-YAP association, remarkably impaired the growth and migration of OS cells in vitro. Moreover to inhibiting YAP activity, our findings indicate that verteporfin also affects the ROCK2 protein and its functions.

conclusionsWe describe the functional connection between ROCK2 and YAP in the regulation of OS cell migration and metastasis formation. These data provide support for the use of verteporfin as a possible therapeutic option to prevent OS cell dissemination.

Indexed as

Adaptor Proteins, Signal TransducingAdolescentAnimalsBone NeoplasmsCell Line, TumorCell MovementCell ProliferationChildDisease Models, AnimalFemaleHeterograftsHumansImmunohistochemistryKaplan-Meier EstimateMiceOsteosarcomaAdaptor Proteins, Signal Transducingrho-Associated KinasesROCK2 protein, humanTranscription FactorsVerteporfinYAP1 protein, humanYAP-Signaling ProteinsMetastasisOsteosarcomaROCK2VerteporfinYAP

Identifiers

PMID31878963
PMCPMC6933701
OpenAlexW2997085878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.